Legal Implications of Peptide Use in Sports

Who these rules apply to

The World Anti-Doping Agency (WADA) publishes a Prohibited List every year, and national agencies such as USADA enforce it under the World Anti-Doping Code. If you compete in a sport that has adopted the Code, the list decides what you can use. Your country's drug laws don't change that. As of October 2026, WADA's 2026 List is in force, and the 2027 List has been published and takes effect on January 1, 2027.

Untested lifters face different questions, covered in our pages on how peptide rules differ between countries and the health risks of peptide use. This page is about the athlete who can be tested.

Where peptides sit on the WADA list

Both BPC-157 and TB-500 are named on WADA's 2026 List, in different sections, as are nearly all the growth hormone peptides sold as research chemicals. The two sections that matter, S2 and S0, both apply at all times, not only on competition days.

S2: peptide hormones and growth factors

S2 covers peptide hormones, growth factors and related substances. Its wording is broad: it bans the listed examples "and other substances with similar chemical structure or similar biological effect(s)." The 2026 List places the peptides lifters ask about most often like this:

• S2.2.3, growth hormone and its fragments: AOD-9604 and hGH 176-191.
• S2.2.4, growth hormone releasing factors: GHRH analogues (CJC-1293, CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (ipamorelin, ibutamoren or MK-677, and others) and GH-releasing peptides (GHRP-1 to GHRP-6, hexarelin).
• S2.3, growth factors: IGF-1 and its analogues, which covers IGF-1 LR3, plus mechano growth factors (MGFs) and "Thymosin-β4 and its derivatives e.g. TB-500".

Mod GRF 1-29, often sold as CJC-1295 without DAC, isn't named, but by the list's own wording it's a GHRH analogue and falls under S2.2.4.

Drug approval doesn't take a substance out of S2. Tesamorelin is an FDA-approved prescription medicine and is still named in S2.2.4. Under Article 4.4 of the Code, an athlete with a real medical need for a listed substance applies for a Therapeutic Use Exemption (TUE) rather than relying on a prescription.

S0: non-approved substances

S0 is the catch-all. The 2026 List prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", and it names BPC-157 directly. As of October 2026, BPC-157 isn't approved as a drug anywhere, so it meets that test.

S0 only catches substances that no other section covers. That's why TB-500 sits in S2.3 and not S0: the growth factor section reaches it first. The difference changes the length of a ban, as the sanctions section below explains.

USADA's advisory on the 2027 List says "peptides" in general are now named as an S0 example, and warns that peptides sold under other names may be prohibited even if the list doesn't name them.

Not every peptide drug is banned. USADA lists semaglutide and tirzepatide in WADA's 2027 Monitoring Program, which means labs track them but athletes aren't sanctioned for using them.

Why "research use only" doesn't help an athlete

Gray-market peptides usually carry labels such as "for research use only" and "not for human consumption." Those labels carry no weight in an anti-doping case. Article 2.1.1 of the Code makes athletes responsible for any prohibited substance, metabolite or marker found in their sample, and a violation doesn't require proof of intent, fault or knowing use. Court of Arbitration for Sport (CAS) decisions call this strict liability. Where the product came from, and what its label said, matters only later, when the length of the ban is decided.

The label also protects sellers less than many buyers assume. In a warning letter dated August 24, 2026, FDA told one research-use peptide seller that, despite those labels, its website showed the products were intended as drugs for human use. The letter pointed to drug claims and to the sale of bacteriostatic water for reconstituting the peptides. For an athlete, being able to buy something legally says nothing about whether it's allowed in sport.

The rules reach beyond the athlete, too. The Code treats trafficking (Article 2.7) and administering a prohibited substance to an athlete (Article 2.8) as violations in their own right, which matters for anyone advising or supplying athletes. Our page on how coaches can talk about peptides without prescribing covers that side.

How peptides are detected

Testing for peptides is uneven. Some have validated urine methods; for others, published methods exist but there's little sign they're catching athletes.

• GHRPs and ipamorelin. A German Sport University Cologne lab published a urine method in 2011 covering GHRP-1, -2, -4, -5 and -6, alexamorelin, ipamorelin and hexarelin, with detection limits of 0.2-1 ng/mL. The authors noted that the established test for injected growth hormone doesn't pick these peptides up. In their excretion study, a GHRP-2 metabolite was still detectable more than 20 hours after a single oral dose, while the intact peptide wasn't found. One small study can't set a detection window, but it doesn't support claims that peptide traces last weeks or months.
• GHRH analogues. A 2021 King's College London study built a method for sermorelin, tesamorelin and both forms of CJC-1295, with detection limits generally at or below 1 ng/mL (WADA's required performance limit). The same paper said that despite admissions and intelligence showing these analogues are used, they didn't appear to have been found in samples by WADA-accredited labs, probably because so little reaches the urine.
• BPC-157. In 2017, the Sports Medicine Research and Testing Laboratory in Salt Lake City identified BPC-157 in confiscated vials and validated a urine method with a detection limit of 0.1 ng/mL. It also found a stable metabolite that makes the test more specific.
• TB-500. The Hong Kong Jockey Club's racing laboratory published a method in 2012 that confirmed TB-500 and its metabolites in urine and plasma from horses given a single dose. We found no published human excretion study.

Labs also have an indirect route. The growth hormone biomarker approach, built to catch recombinant growth hormone, combines IGF-1 and P-III-NP (a collagen turnover marker) into a GH-2000 score. In a small Swedish study, all four men given GHRH rose above their own baseline-derived thresholds when the markers were tracked over time. The authors called this promising for men, but the markers swing much more across the menstrual cycle, which makes it harder to use in women. Four men aren't a validated test, though the results suggest a peptide-driven rise in IGF-1 can show up in an athlete's blood profile.

What a positive test costs

The length of a ban depends on whether the substance is "specified," and the 2026 List says which applies to each section. As of October 2026, Article 10.2 of the 2021 Code sets the standard periods:

• S2 substances (TB-500, the growth hormone peptides, IGF-1 analogues) are non-specified. The ban is four years unless the athlete shows the violation wasn't intentional, in which case it's two.
• S0 substances (BPC-157) are specified. The ban is two years, rising to four if the anti-doping organization shows the use was intentional.

Article 10.6 allows shorter bans in narrow cases where the athlete establishes no significant fault or negligence. Because intent can double the penalty, how the athlete got the product and why they used it can weigh heavily at a hearing. The ethical questions athletes weigh before that point are covered in our look at peptide ethics in sport.

What we still don't know

• Status of newly approved peptides. Elamipretide (SS-31) and bremelanotide (PT-141) are now FDA-approved medicines, and neither is named on the 2026 List. Since S0 covers only unapproved substances, we couldn't confirm how WADA treats them as of October 2026.
• How often peptides turn up in real samples. Validated methods exist for BPC-157, GHRPs and GHRH analogues, but the 2021 GHRH paper found no sign those analogues had been reported in athlete samples. We didn't find peptide-specific testing figures.
• Human detection windows. No published human excretion study for BPC-157 or TB-500 turned up, so nobody can say how long either stays detectable in people.
• The 2027 List in detail. USADA describes the 2027 changes as relatively minor, and we didn't review the full 2027 text. Athletes should check the list itself, or Global DRO, once it takes effect.